DALIRESP

This brand name is authorized in Estonia, Lithuania, United States

Active ingredients

The drug DALIRESP contains one active pharmaceutical ingredient (API):

1 Roflumilast UNII 0P6C6ZOP5U - ROFLUMILAST

Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD. Read about Roflumilast

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DALIRESP Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03DX07	Roflumilast	R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1518780, 1518791, 1518803
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1059263, 1059264, 1059265
Country: US	FDA, National Drug Code	Identifier(s): 0310-0088, 0310-0095